Publication | Closed Access
Results from a 9‐year Intensive Safety Surveillance Scheme (IS<sup>3</sup>) in miglustat (Zavesca<sup>®</sup>)‐treated patients
15
Citations
10
References
2015
Year
Overall, the results of this long-term safety surveillance programme were in line with the well-known, documented safety profile of miglustat.
| Year | Citations | |
|---|---|---|
Page 1
Page 1